Collaborations

sphingotec takes a collaborative approach in the discovery and validation of novel biomarkers. Contact us with your ideas and interest at: collaborations@sphingotec.de

Partnerships

For the commercialisation of our microtiter plate assays as well as our Nexus iB10 point-of-care platform and acute care assay portfolio we work with partners world wide. If you are interested in distributing our products, please contact us at: commercial@sphingotec.de

Business Development

For broad market adoption of our first-in-class biomarkers, we partner with global and regional IVD companies. If you are interested in obtaining licenses to our proprietary biomarkers, please contact us at: business@sphingotec.de

Our Mission

To improve patient outcomes with innovative diagnostic solutions for acute care and preventive medicine: Actionable insights in real-time.

SphingoTec GmbH
Neuendorfstr. 15A, 16761 Hennigsdorf
Telefon: +49 3302 20565 0
E-Mail: info@sphingotec.de
www.sphingotec.com
The Biomarker Company

Sphingotec develops and markets innovative in vitro diagnostic (IVD) tests for novel and proprietary blood-based protein biomarkers for the diagnosis, outcome prediction, and monitoring of acute medical conditions, such as acute heart failure, circulatory failure and acute kidney injury. Sphingotec’s first-in-class biomarker tests are made available on its proprietary whole-blood point-of-care Nexus IB10 platform for convenient and rapid testing in near-patient and laboratory settings alongside a broad portfolio of standard-of-care test for acute care. For high-throughput testing in central laboratories, Sphingotec partners with global IVD players. Beyond acute care, Sphingotec develops novel biomarkers for preventive medicine in obesity, cancer, and cardiovascular diseases.

### IVD Assays

<table>
<thead>
<tr>
<th>Biomarker Discovery</th>
<th>Biomarker Validation</th>
<th>sphingotest® MTP Assay</th>
<th>IB10 sphingotest® POC Assay</th>
<th>Central Lab Assay</th>
</tr>
</thead>
<tbody>
<tr>
<td>DPP3 – short-term organ dysfunction</td>
<td>penKid® – kidney function</td>
<td>[ ]</td>
<td>[ ]</td>
<td>[ ]</td>
</tr>
<tr>
<td>bio-ADM® – vascular integrity</td>
<td>pro-NT® – breast cancer risk prediction</td>
<td>[ ]</td>
<td>[ ]</td>
<td>[ ]</td>
</tr>
<tr>
<td>pro-ENK® – breast cancer risk prediction</td>
<td>wr-hGH – cardiovascular mortality</td>
<td>[ ]</td>
<td>[ ]</td>
<td>[ ]</td>
</tr>
<tr>
<td>Sel-P – stroke &amp; acute myocardial infarction</td>
<td>[ ]</td>
<td>[ ]</td>
<td>[ ]</td>
<td>[ ]</td>
</tr>
</tbody>
</table>

1 The information contained in this communication does not constitute nor imply an offer to sell in or transfer to the United States of America or Canada any IVD product. No IVD product by Sphingotec GmbH or Nexus Dx Inc. is available for sale in the United States of America or Canada. The analytical and clinical performance characteristics of any IVD product by Sphingotec GmbH or Nexus Dx Inc. may be sold at some future point in time in the U.S. have not yet been established.

### Medicine4Future Initiative

Sphingotec and its subsidiary Nexus Dx Inc. together with 4TEEN4 Pharmaceuticals GmbH and Adrenomed AG have the common goal to improve the management of critically ill patients and in future help preventing the manifestation of common diseases by developing first-in-class diagnostics and targeted therapies in a hypothesis-driven approach that is deeply rooted in a profound understanding of disease biology. They form the Medicine4Future Initiative established by Dr. Andreas Bergmann, Chief Scientific Officer of the founders and former Chief Research Officer of B.R.A.H.M.S. AG where he was responsible for the development of the gold standard sepsis biomarker Procalcitonin (B.R.A.H.M.S. PCT®).

### Driving Biomarker Adoption on Multiple Platforms

- **High-Throughput Solutions** for central laboratories on partner platforms
- **Rapid Testing** in near-patient settings & labs on Nexus IB10 POC Platform
- **Microwell Plate (MTP) Assays** for validation & first in-market studies